Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study.

Authors

• William Kelly

Publication/Presentation Date

5-2014

Volume

32

Issue

15

Published In/Presented At

DOI: 10.1200/jco.2014.32.15_suppl.4513

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article